Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.
Morelli
Micaela
M
Department of Toxicology and Centre of Excellence for Neurobiology of Dependence, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy. morelli@unica.it
D000241:Adenosine / Q000494:pharmacology / Q000627:therapeutic use; D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002110:Caffeine / Q000494:pharmacology / Q000627:therapeutic use; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010166:Palliative Care; D010300:Parkinson Disease / Q000188:drug therapy* / Q000517:prevention & control*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats
D058917:Adenosine A2 Receptor Antagonists; D000978:Antiparkinson Agents; D000697:Central Nervous System Stimulants; D018696:Neuroprotective Agents; D002110:Caffeine; D000241:Adenosine